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BACKGROUND: a-Tocopherol ether-linked acetic acid (a-TEA) is a promising agent for cancer prevention/therapy based on its
antitumour actions in a variety of cancers.
METHODS: Human breast cancer cells, MCF-7 and HCC-1954, were used to study the effect of a-TEA using Annexin V/PI staining,
western blot analyses, and siRNA knockdown techniques.
RESULTS: a-Tocopherol ether-linked acetic acid suppressed constitutively active basal levels of pAKT, pERK, pmTOR, and their
downstream targets, as well as induced both cell types to undergo apoptosis. Phosphoinositide 3-kinase (PI3K) inhibitor wortmannin
suppressed pAKT, pERK, pmTOR, and their downstream targets, indicating PI3K to be a common upstream mediator. In addition,
a-TEA induced increased levels of pIRS-1 (Ser-307), a phosphorylation site correlated with insulin receptor substrate-1 (IRS-1)
inactivation, and decreased levels of total IRS-1. Small interfering RNA (siRNA) knockdown of JNK blocked the impact of a-TEA on
pIRS-1 and total IRS-1 and impeded its ability to downregulate the phosphorylated status of AKT, ERK, and mTOR. Combinations of
a-TEAþMEK or mTOR inhibitor acted cooperatively to induce apoptosis and reduce basal levels of pERK and pmTOR. Importantly,
inhibition of MEK and mTOR resulted in increased levels of pAKT and IRS-1, and a-TEA blocked them.
CONCLUSIONS: Downregulation of IRS-1/PI3K pathways via JNK are critical for a-TEA and a-TEAþMEK or mTOR inhibitor-induced
apoptosis in human MCF-7 and HCC-1954 breast cancer cells.
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The PI3K, AKT, ERK, and mTOR prosurvival mediators are
important therapeutic targets, as they are constitutively activated
in many cancers and contribute to cancer progression by
promoting cellular proliferation and inhibiting cell death signalling
pathways (Falasca, 2010). Phosphoinositide 3-kinase (PI3K)
is activated at the cell membrane by tyrosine kinase growth
factor receptors, such as members of the epidermal growth factor
receptor family (EGFR and Her-2), and by the insulin-like growth
factor-1 receptor (IGFR), as well as its downstream signalling
substrate IRS-1 (insulin receptor substrate-1; Schlessinger, 2000).
Phosphoinositide 3-kinase promotes cancer cell survival by
activation of downstream mediators AKT and Ras, the latter
leading to ERK activation (McCubrey et al, 2007). AKT exerts
its survival role via a diverse array of substrates, which control
key cellular processes, including apoptosis, cell cycle progression,
transcription, and translation (Chang et al, 2003). A major down-
stream substrate of AKT is the serine/threonine kinase mTOR.
AKT can directly phosphorylate mTOR at ser-2448 and activate it,
as well as cause indirect activation of mTOR by phosphorylating
and inactivating TSC2 (tuberous sclerosis complex 2, also called
tuberin). The raptor–mTOR complex signals to its down-
stream effectors S6 kinase/ribosomal protein S6 (p70S6K) and
the eIF4E-binding protein (p4E-BP1) to control transcription and
translation, which selectively regulates multiple proteins that
control cell cycle and apoptosis (Gibbons et al, 2009). Additionally,
AKT can directly regulate apoptosis by phosphorylating and
inactivating proapoptotic proteins such as Bad and caspase-9
(Datta et al, 1997; Cardone et al, 1998; Mabuchi et al, 2002).
Extracellular signal-regulated kinase (ERK) exerts its antiapoptotic
effects by phosphorylating and inactivating Bad (Mabuchi et al,
2002). As with most intracellular signalling cascades, cross-talk
and negative and positive feedback loops complicate final
signalling outcomes.
For example, the mTOR substrate p70S6K can ultimately
diminish prosurvival signalling via PI3K/AKT by catalysing an
inhibitory phosphorylation site on insulin receptor substrate-1, an
upstream mediator of PI3K (Wan et al, 2007). Likewise, ERK can
diminish prosurvival signalling by PI3K/AKT via p70S6K (Jiang
et al, 2009). Therefore, although ERK and mTOR showed potential
as anticancer targets, inhibitors of ERK or mTOR alone are limited
in clinical application because of the mitigation of these negative
feedback loops essential for controlling AKT activity (Sun et al,
2005). Thus, this more in-depth understanding of signalling
pathways suggests that ERK or mTOR inhibitors need to be
combined with agents that can circumvent the loss of negative
feedback controls on AKT and/or effectively block AKT activity.
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sa-Tocopherol ether-linked acetic acid (a-TEA) is a promising
agent for cancer prevention/therapy based on its antitumour
actions reported in several in vitro and in vivo studies on a variety
of cancers, including human oestrogen-responsive and non-
responsive breast cancers (Anderson et al, 2002; Lawson et al,
2004; Shun et al, 2004; Hahn et al, 2006; Yu et al, 2006; Jia et al,
2008a,b; Wang et al, 2008; Hahn et al, 2009; Shun et al, 2010).
These previous studies showed that a-TEA induces apoptosis in
human breast cancer cells via activation of proapoptotic extrinsic
death receptor Fas and DR5 as well as activation of a JNK/p73/
Noxa pathway, leading to activation of caspase-8 and mitochon-
drial-dependent apoptosis (Shun et al, 2004; Wang et al, 2008;
Yu et al, 2010). In this study, we demonstrate that a-TEA induces
apoptosis not only by activation of pro-apoptotic pathways
but also by targeting IRS-1/PI3K growth/survival pathways
to suppress multiple prosurvival factors via c-Jun N-terminal
kinase (JNK). Lessons learned from this study are that a-TEA in
combination with ERK or mTOR inhibitors is an effective
anticancer strategy and lays the groundwork for a mechanism-
based combinational therapeutic strategy for employing ERK and
mTOR inhibitors more effectively in the clinic.
MATERIALS AND METHODS
Chemicals
a-Tocopherol ether-linked acetic acid (FW¼488.8) was prepared
in-house as described previously (Lawson et al, 2004). Map kinase
kinase (MEK) inhibitor (U01260) and PI3K inhibitor (wortman-
nin) were purchased from Cell Signaling Technology (Beverly, MA,
USA). Mammalian target of rapamycin (mTOR) inhibitor (rapa-
mycin) and JNK inhibitor (SP600125) were purchased from
Calbiochem (La Jolla, CA, USA).
Cell culture
The oestrogen receptor-negative human breast cancer cells,
HCC-1954, were obtained from the American Type Culture
Collection (Manassas, VA, USA). The oestrogen-responsive human
breast cancer cells, MCF-7, were originally provided by Dr Suzanne
Fuqua (Baylor College of Medicine, Houston, TX, USA). The
MCF-7 cells were cultured as previously described (Wang et al,
2008). The HCC-1954 cells were cultured in RPMI media with 10%
FBS. For experiments, FBS was reduced to 2% and cells were
allowed to attach overnight before treatments. a-Tocopherol ether-
linked acetic acid (40mM) dissolved in ethanol served as stock
solution. Equivalent final concentrations of ethanol (0.05–0.1%)
for concentration of a-TEA used served as vehicle controls (VEH).
Western blot analyses
Whole-cell protein lysates and western blot analyses were
conducted as described previously (Jia et al, 2008a,b). Proteins
at 20–50mg per lane were separated by SDS–PAGE and
transferred to nitrocellulose (Optitran BA-S supported nitro-
cellulose; Schleicher and Schuell, Keene, NH, USA). Antibodies
to the following proteins were used: poly (ADP-ribose) polymerase
(PARP), phospho-JNK (pJNK thr-183/tyr-185), phospho-ERK
(pERK thr-202/tyr-204), total ERK and phospho-caspase-9
(pcaspase-9 ser-196) (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), Phospho-AKT (pAKT ser-473), pAKT (ser-308), total AKT,
phospho-GSK (pGSK a/b ser-21/9), total GSK a/b, phospho-Bad
(pBad ser-136), phospho-Bad (pBad ser-112), total Bad, total
casapse-9, phospho-p90RSK (pp90RSK ser-380), total p90RSK,
phospho-mTOR (pmTOR ser-2448), total mTOR, phospho-p70S6K
(pp70S6K thr-389), total p70S6K, phospho-4E-BP1 (p4E-BP1
thr-37/46), total 4E-BP1, phospho-IRS (pIRS ser-307), total IRS,
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Cell
Signaling Technology).
Small interfering RNA (siRNA) transfection
A scrambled RNA duplex that does not target any known
genes was used as a nonspecific negative control for RNAi
(referred to as control siRNA) (Ambion, Austin, TX, USA).
Transfection of siRNAs to AKT1, AKT2, JNK1/2, or control
(Ambion) was performed in 100mm
2 cell culture dishes at a
density of 2 10
6 cells per dish using Lipofectamine-2000
(Invitrogen, Carlsbad, CA, USA) and siRNA duplex, resulting in
a final siRNA concentration of 30nM following the company’s
instructions. At 1 day after transfection, the cells were re-cultured
in 100mm
2 dishes at 2 10
6 cells per dish and incubated for 1 day
followed by treatments.
Quantification of apoptosis
Apoptosis was quantified by Annexin V-FITC/propidium iodide
(PI) assay following the manufacturer’s instructions. The Annexin
V-FITC/PI assay measures the amount of phosphatidylserine
on the outer surface of the plasma membrane (a biochemical
alteration unique to membranes of apoptotic cells) and the amount
of PI, a dye that does not cross the plasma membrane of viable
cells but readily enters dead cells or cells in the late stages of
apoptosis and binds DNA. Fluorescence was measured using
fluorescence activated cell sorter (FACS) analyses with a FACS-
Calibur flow cytometer, and data were analysed using CellQuest
software (BD Biosciences, San Jose, CA, USA). Cells displaying
phosphatidylserine on their surface (i.e., positive for annexin-V
fluorescence) were considered to be apoptotic.
Statistical analysis
Apoptosis data were analysed using a one-way analysis of variance
(ANOVA) followed by Tukey’s test for comparison of more than
two treatments or a two-tailed Student’s t-test for comparison
between two treatments to determine statistical differences.
Differences were considered statistically significant at Po0.05.
RESULTS
a-TEA induces apoptosis in HCC-1954 and MCF-7 human
breast cancer cells
Human breast cancer cells, MCF-7 and HCC-1954, were treated
with a-TEA at different doses (Figure 1A) or for different periods
of time (Figure 1B). Apoptosis was quantified by FACS analyses of
cells labelled with FITC-Annexin V. Treatment of MCF-7 cells with
a-TEA at 20 or 40mM and HCC-1954 cells at 10 or 20mM for 24h
induced both cell types to undergo apoptosis in a dose-dependent
manner, with HCC-1954 cells exhibiting greater sensitivity than
MCF-7 cells (Figure 1A). Treatment of the MCF-7 and HCC-1954
cells with a-TEA at 40 and 20mM, respectively, for 9, 15, and 24h
induced apoptosis in a time-dependent manner (Figure 1B). These
data show that a-TEA is a potent apoptotic inducer of both
ER-responsive and nonresponsive human breast cancer cells.
a-TEA reduces high basal levels of phosphorylated AKT,
ERK1/2, and mTOR
Vehicle-treated HCC-1954 and MCF-7 cells express high levels of
active AKT (pAKT) and phosphorylated downstream substrates
GSK (pGSK), Bad (pBad), and caspase 9 (pcaspase-9). Treatment of
HCC-1954 (20mM) and MCF-7 cells (40mM) with a-TEA for 9, 15,
and 24h: (1) reduces levels of pAKT (both Ser-473 and Ser-308)
as well as its downstream substrates pGSK (a/b) (Ser-21/9), pBad
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s(Ser-136), and pcaspase-9 (Ser-196) and increases cleaved caspase 9
in a time-dependent manner (Figure 2A), (2) downregulates
pERK1/2 and its substrates pp90SK (Ser-380) and pBad (Ser-112)
(Figure 2B), and (3) downregulates pmTOR (Ser-2448) and its
substrates pp70S6K (Thr-389) and p4E-BP1 (Thr-37/46) (Figure 2C).
These data show that a-TEA suppresses the active forms of
AKT, ERK, mTOR, and their downstream substrates, resulting in
activation of proapoptotic mediators Bad and caspase-9.
PI3K inhibitor (wortmannin) suppresses pAKT, pERK1/2,
and pmTOR in MCF-7 cells
To better understand how the basal levels of pAKT, pERK, and
pmTOR are regulated, MCF-7 cells were treated with 1mM
wortmannin (PI3KI) for 4 and 8h. Wortmannin reduced the
phosphorylated forms of: (1) AKT and its substrates pBad
(Ser-136) and pcaspase-9 (Ser-196) (Figure 3A), (2) ERK1/2 and
its substrate pBad (Ser-112) (Figure 3B), and pmTOR (Ser-2448) and
its substrate p4E-BP1 (Thr 37/46) (Figure 3C), indicating that PI3K
is a major contributor to the basal levels of AKT, ERK, and mTOR.
a-TEA induces increased levels of phospho-IRS-1 (Ser-307)
and decreased levels of total IRS-1 via JNK
To identify a common upstream factor that might account for how
a-TEA suppresses pAKT, pERK, and pmTOR in unison, the effect
of a-TEA on phospho-IRS-1 (pIRS-1 Ser-307) was examined.
Ser-307 is a phosphorylation site regulated by JNK for inactivation
of IRS (Mamay et al, 2003) via reduction of total IRS protein levels
(Hiratani et al, 2005). As a-TEA has been reported to induce a
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Figure 2 a-Tocopherol ether-linked acetic acid (a-TEA) suppresses
AKT, ERK, mTOR, as well as their downstream targets. HCC-1954 and
MCF-7 cells were treated with 20 and 40mM a-TEA, respectively, for 9, 15,
and 24h. (A) Protein levels of pAKT (Ser-473 and Ser-308), pGSK (a/b)
(Ser 21/9), pBad (Ser-136), pcaspase-9 (Ser-196), as well as levels of total
AKT, GSK, Bad, and caspase-9 were determined by western blot analyses.
(B) Protein levels of pERK1/2, pp90RSK (Ser-380), and pBad (Ser-112),
as well as total ERK, p90RSK, and Bad were determined by western blot
analyses. (C) Protein levels of pmTOR (Ser-2448), pp70S6K (Thr-389), and
p4E-BP1 (Thr-37/46), and levels of total mTOR, p70S6K, and 4E-BP1 were
determined by western blot analyses. Data are representative of two
separate experiments.
90
100 MCF-7
HCC-1954
*
40
50
60
70
80
*
0
10
20
30
A
p
o
p
t
o
s
i
s
 
(
%
)
VEH
* *
90
100
MCF-7 (-TEA 40 M)
HCC-1954 (-TEA 20 M)
*
-TEA (M)
50
60
70
80
* *
*
0
10
20
30
40
A
p
o
p
t
o
s
i
s
 
(
%
)
*
*
24
-TEA VEH
40/20 20/10
24 (h) 15 9
Figure 1 a-Tocopherol ether-linked acetic acid (a-TEA) induces
apoptosis in human breast cancer cells in a dose- and time-dependent
manner. (A) MCF-7 and HCC-1954 cells were treated with different
concentrations of a-TEA for 24h and the proapoptotic property of a-TEA
was evaluated by FACS/Annexin V assay. (B) MCF-7 and HCC-1954 cells
were treated with 40 and 20mM a-TEA, respectively, for different times,
and the proapoptotic property of a-TEA was evaluated by FACS/
Annexin V assay. Data are the mean±s.d. of different independent
experiments. *Significantly different from VEH (Po0.05).
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sprolonged activation of JNK (Shun et al, 2004; Yu et al, 2006;
Jia et al, 2008a,b; Wang et al, 2008), IRS-1 may be a promising
upstream target for a-TEA-mediated events. The HCC-1954 and
MCF7 cells were treated with 20 and 40mM a-TEA, respectively, for
9, 15, and 24h. a-Tocopherol ether-linked acetic acid induced
increased levels of pJNK2/1, increased levels of pIRS-1 (ser-307),
and reduced levels of total IRS-1 in both cell lines (Figure 4A).
Knockdown of JNK using a chemical inhibitor SP600125 (JNKI)
(Figure 4B) or siRNA (Figure 4C) blocked the ability of a-TEA to
increase pIRS-1 (Ser-307) and decrease levels of total IRS-1
protein, and suppressed the ability of a-TEA to reduce pAKT
(Ser-473), pERK1/2, and pmTOR (Ser-2448). These data suggest
that downregulation of IRS-1 is involved in the ability of a-TEA to
suppress AKT, ERK, and mTOR signalling and demonstrated that
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Figure 3 Extracellular signal-regulated kinase (ERK) and mTOR are downstream targets of PI3K. MCF-7 cells were treated with 1mM PI3K inhibitor
wortmannin for 4 and 8h. (A) Protein levels of pAKT (Ser-473), pBad (Ser-136), and pcaspase-9 (Ser-196), and levels of total AKT, Bad, and caspase-9 were
determined by western blot analyses. (B) Protein levels of pERK1/2 and pBad (Ser-112) and total levels of ERK1/2 and Bad were determined by western
blot analyses. (C) Protein levels of pmTOR (Ser-2448) and p4E-BP1 (Thr-37/46), and total levels of mTOR and 4E-BP1 were determined by western blot
analyses. Data are representative of two separate experiments.
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Figure 4 a-Tocopherol ether-linked acetic acid (a-TEA) downregulates AKT, ERK, and mTOR via JNK-mediated decrease in IRS protein expression.
(A) HCC-1954 and MCF-7 cells were treated with 20 and 40mM a-TEA, respectively, for 9, 15, and 24h. Western blot analyses were performed to detect
phospho-JNK2/1, pIRS-1 (Ser-307), and total IRS, with GAPDH serving as loading control. (B) MCF-7 cells were treated with 10mM JNK inhibitor SP600125
(JNKI)þ40mM a-TEA for 18h. Protein levels of pAKT (Ser-473), pERK1/2, pmTOR (Ser-2448), pIRS-1 (Ser-307), and total levels of AKT, ERK1/2, mTOR,
and IRS-1 were determined by western blot analyses, with GAPDH serving as lane control. (C) MCF-7 cells transfected with siRNA to JNK or control siRNA
were treated with 40mM a-TEA for 18h. Protein levels of pAKT (Ser-473), pERK1/2, pmTOR (Ser-2448), pIRS-1 (Ser-307), and levels of total AKT, ERK,
mTOR, and IRS were determined by western blot analyses, with GAPDH as lane control. Data are representative of two separate experiments.
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sJNK is involved in this event via phosphorylation of IRS-1 at
Ser-307, leading to its degradation.
Inhibitors of PI3K, MEK/ERK, and mTOR as well as siRNA
to AKT1 and AKT2 cooperated with a-TEA to induce
apoptosis
To determine the effects of inhibition of members of the PI3K
pathway on a-TEA-induced apoptosis, HCC-1954 and MCF-7 cells
were cultured with 10 and 20mM a-TEA, respectively, plus 1mM
PI3K inhibitor (PI3KI) wortmannin, 10mM MEK inhibitor (MEKI)
U01260, and 50nM mTOR inhibitor (mTORI) rapamycin for 18h.
Single treatments with a-TEA or inhibitors induced low levels of
apoptosis, whereas combinations of a-TEA plus each of the three
inhibitors individually significantly enhanced induction of apop-
tosis in both cell types in comparison with single treatments
(Figure 5A and B). Both a-TEA and PI3K inhibitors reduced levels
of pAKT (Ser-473), pERK1/2, and pmTOR (Ser-2448), and the
combination of a-TEAþPI3K inhibitor acted cooperatively to
enhance PARP cleavage and to reduce levels of pAKT (Ser-473),
pERK1/2, and pmTOR (Ser-2448) when compared with individual
treatments or control (Figure 5C). Both MEK and mTOR inhibitors
enhanced a-TEA-induced PARP cleavage and cooperatively
enhanced a-TEA inhibition of pERK1/2 and pmTOR, respectively
50
60
70
80
50
60
70
*
* *
*
* *
A
p
o
p
t
o
s
i
s
 
(
%
)
10
20
30
40
10
20
30
40
A
p
o
p
t
o
s
i
s
 
(
%
)
0 0
++ – – –
VEH
VEH
tAKT 
Pro-PARP
c-PARP
pAKT (Ser-473) 
+ + – –
Pro-PARP
cPARP
pERK (1/2) 
-TEA
(20 M) -TEA
(20 M)
tERK (1/2)
pmTOR (Ser-2448)
pERK (1/2) 
pmTOR (Ser-2448)
tmTOR
tERK (1/2)
MCF-7
tmTOR
MCF-7
40
45
50 VEH
-TEA (20 M) * *
10
15
20
25
30
35
A
p
o
p
t
o
s
i
s
 
(
%
)
0
5
siRNA
MCF-7
Pro-PARP
c-PARP
-TEA (20 M) ++ –+ – –
siRNA
pAKT (Ser-473)
tAKT1
tAKT2
GAPDH
tmTOR
pmTOR (Ser-2448)
pERK (1/2) 
MCF-7
VEH MEKI mTORI
-TEA (20 M) –
tAKT
pAKT (Ser-473) 
tIRS
GAPDH
tAKT  
VEH
PI3KI + -TEA
PI3KI
MEKI
MEKI + -TEA
mTORI
mTORI + -TEA
-TEA
VEH
PI3KI + -TEA
PI3KI
MEKI
MEKI + -TEA
mTORI
mTORI + -TEA
-TEA
PI3KI
mTORI MEKI
+
AKT2 AKT 1 Control
AKT2 AKT1 Control
+ – + +–
Figure 5 Inhibitors of PI3K, MEK/ERK, mTOR, as well as siRNAs to AKT1 and AKT2 enhance a-TEA-induced apoptosis. (A and B) HCC-1954 and MCF-
7 cells were treated with 1mM PI3K inhibitor wortmannin (PI3KI), 10mM MEK inhibitor U01260 (MEKI), or 50nM mTOR inhibitor rapamycin (mTORI) plus
10 and 20mM of a-TEA for 18h, respectively. Apoptosis was determined by Annexin V/PI staining. (C and D) Protein levels of cleaved PARP, pAKT (Ser-
473), pERK1/2, and pmTOR (Ser-2448) as well as levels of total AKT, ERK1/2, and mTOR were determined by western blot analyses in MCF-7 cells treated
with the three inhibitors plus a-TEA. (E) MCF-7 cells transfected with siRNAs to AKT1, AKT2, or control was treated with 20mM a-TEA for 18h. Apoptosis
was determined by Annexin V/PI staining. (F) Protein levels of cleaved PARP, pAKT (Ser-473), pmTOR (Ser-2448), pERK1/2, and levels of total AKT1,
AKT2, and mTOR were determined by western blot analyses. Levels of GAPDH served as lane controls. (G) MCF-7 cells treated with 10mM MEK inhibitor
U01260 (MEKI) or 50nM mTOR inhibitor rapamycin (mTORI) plus 20mM of a-TEA for 18h. Protein levels of pAKT (Ser-473), AKT, IRS-1, and GAPDH
were determined by western blot analyses. Data in (C, D, F, and G) are representative of two separate experiments. Data in (A, B, and E) are presented as
mean±s.d. of three independent experiments. *Significantly different from control (Po0.05).
a-TEA triggers apoptosis by inhibiting survival pathways
R Tiwary et al
105
British Journal of Cancer (2011) 104(1), 101–109 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(Figure 5D). Combinations of a-TEAþAKT1 or 2 siRNA acted
cooperatively to induce apoptosis (Figure 6E) and inhibit pAKT
(Ser-473) and total AKT1 and AKT2, respectively, as well as
pmTOR (Ser-2448), but had no effect on basal levels of pERK1/2,
showing that the ERK signalling pathway is independent of AKT
signalling (Figure 5F). Taken together, data in Figure 5 show that
a-TEA can downregulate the basal levels of active AKT, ERK1/2,
and mTOR, and can act cooperatively with either chemical- or
genetic-based inhibitors of these prosurvival mediators to enhance
breast cancer cell death.
a-TEA blocked the ability of MEK and mTOR inhibitors to
induce increased levels of pAkt and IRS
It has been reported that MEK and mTOR inhibitors induce
increased levels of phospho-Akt via negative feedback regulation
of IRS (Wan et al, 2007; Jiang et al, 2009). As expected, MEK and
mTOR inhibitors induced increased levels of pAKT and IRS-1, an
outcome that limits their clinical anticancer efficacy; importantly,
co-treatment with a-TEA was able to block this counterproductive
increase in these potent prosurvival mediators (Figure 5G).
Based on these data, we hypothesise a signalling pathway
depicting cross-talk between survival and death signalling path-
ways in a-TEA alone and a-TEAþMEK or mTOR inhibitor-
induced apoptosis in human breast cancer cells (Figure 6). In
the untreated cells, IGF/IGFR via downstream mediator IRS-1
regulates two distinct signalling pathways (PI3K and Ras) that
contribute to basal levels of activated AKT, ERK, and mTOR.
Activated AKT and ERK1/2 phosphorylate proapoptotic mediators
Bad and caspase-9, thereby inhibiting their proapoptotic actions
and thus enhancing cancer cell survival. Both ERK and mTOR
trigger a negative feedback loop via their substrate p70S6K that
downregulates IRS-1 signalling. Previous studies (non-bolded
signalling pathway) have shown that a-TEA induces apoptosis
via upregulation of cell surface death receptor-mediated caspase-8
and mitochondrial-dependent pathways (Shun et al, 2004; Yu et al,
2006; Jia et al, 2008b; Tiwary et al, 2010). Previous studies have
also identified JNK as a key player in a-TEA-induced apoptosis
(Shun et al, 2004; Yu et al, 2006; Jia et al, 2008a,b; Wang et al,
2008). In addition to signalling apoptosis via p73/Noxa (Wang
et al, 2008) and a Fas/JNK positive feedback loop (Jia et al,
2008a,b), we report here that JNK suppresses PI3K prosurvival
signalling pathways via phosphorylation (inactivation and degra-
dation) of IRS-1. As IRS-1 has an apical role in activation of AKT,
ERK, and mTOR survival signalling pathways via PI3K, elimina-
tion of IRS-1 deprives the cells of these signalling mediators as
well as restores proapoptotic activity by Bad and caspase-9 via
their dephosphorylation, leading to cell death by apoptosis. In
summary, the results reported in this study help clarify why a-TEA
is such a potent apoptotic agent in human breast cancer cell lines,
and suggest potential utility for a-TEA in combination therapy
with ERK and mTOR inhibitors.
DISCUSSION
These studies demonstrate, for the first time, that a-TEA
suppresses AKT- and ERK-mediated antiapoptotic events, namely,
inhibitory phosphorylation of two proapoptotic factors Bad
and caspase-9. Additionally, a-TEA suppression of AKT leads to
decreases in mTOR activity, as measured by reduction in
downstream mediators p4E-BP1 and p70S6K. Functional knock-
down assessments indicate that a-TEA-mediated activation of JNK
has a critical role in these events via downregulation of IRS-1. The
following sequence of events are proposed for a-TEA-mediated
apoptosis: a-TEA inhibits PI3K via JNK-mediated phosphorylation
of IRS-1 at ser-307, resulting in inactivation of AKT/mTOR and
Ras/ERK, which act cooperatively in a-TEA-induced mitochon-
drial-dependent proapoptotic events via activation of Bad and
caspase-9. Especially noteworthy is that these studies showed that
the harmful outcome of drug inhibition of either ERK or mTOR,
namely, activation of AKT, could be prevented by combination
treatment with a-TEA. In summary, data show that a-TEA
suppression of IRS-1 not only has an important role in a-TEA-
induced apoptosis but can also suppress activation of AKT
induced by ERK and mTOR inhibitors, suggesting that a-TEA
might improve clinical outcomes of treatment with ERK or mTOR
inhibitors.
The pleiotropic effects of PI3K/AKT signalling on inhibition of
apoptosis have been reported to be a major mechanism for drug
resistance (McCubrey et al, 2007; Gibbons et al, 2009; Falasca,
2010). Therefore, identification of agents that can both block
survival and induce death signalling pathways should aid
development of strategies to sensitise drug-resistant breast cancer
cells. a-Tocopherol ether-linked acetic acid has been reported to
suppress AKT in prostate and ovarian cancer cells and that
suppression of AKT contributes to a-TEA-induced apoptosis
-TEA
IGF
Fas/DR5 IGFR
ER stress
IRS-1
PI3K
Caspase-8
p73
JNK
tBid
AKT
Mitochondria
Bax
Bad
mTOR
Noxa
Caspase-9
Apoptosis
Ras
ERK
p70S6K
Figure 6 Schematic diagram depicting signalling pathways that are
involved in a-TEA alone and a-TEAþMEK or mTOR inhibitor-induced
apoptosis. Schematic diagram depicts cross-talk between survival and death
signalling pathways in a-TEA alone and a-TEAþMEK or mTOR inhibitor-
induced apoptosis in human breast cancer cells. Constitutively active insulin
receptor substrate-1 (IRS-1) activates AKT and ERK via phosphorylations
mediated by PI3K and Ras, respectively, leading to subsequent phosphor-
ylation events that inhibit proapoptotic mediators Bad and caspase 9, and
activate prosurvival mTOR. Beneficial antitumour actions by inhibitors of
mTOR (rapamycin) and ERK (MEK inhibitor) are compromised by
elimination of mTOR or ERK-regulated p70S6K negative loop inhibiting
IRS-1 signalling. The loss of this negative feedback loop results in continued
activation of AKT signalling and inhibition of apoptosis by inactivation of Bad
and caspase 9. a-Tocopherol ether-linked acetic acid (a-TEA) induces
death receptor-mediated apoptosis (depicted by non-bolded signalling
pathways described in references Shun et al, 2004; Yu et al, 2006; Jia et al,
2008a,b; Wang et al, 2008) with involvement of prolonged activation of
JNK. Our data show that JNK is activated by endoplasmic reticulum (ER)
stress (Tiwary et al, 2010). Active JNK blocks IRS-1 signalling, thereby
downregulating downstream survival signalling mediators, resulting in the
activation of proapoptotic mediators Bad and caspase 9, leading to
promoting mitochondria-dependent apoptosis. Combinations of sub-
optimal levels of a-TEA plus mTOR or MEK inhibitors act synergistically
to induce apoptosis by reduction of AKT- and ERK-mediated inhibition of
proapoptotic factors Bad and caspase 9.
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cancer cells, a-TEA suppression of AKT causes activation of Fox-1,
a proapoptotic transcription factor capable of triggering apoptosis
via upregulation of Bim (Jia et al, 2008a,b). In ovarian cancer cells,
a-TEA suppresses c-FLIP and survivin protein expression via
AKT-mediated events (Shun et al, 2010). In this study we report
that a-TEA suppression of AKT via targeting IRS-1/PI3K leads to
activation of proapoptotic Bad and caspase-9 in human breast
cancer cells.
Bad is a proapoptotic member of the Bcl-2 family, which belongs
to the BH3-only protein family comprising Bad, Bik, Bmf, Hrk,
Noxa, tBid, Bim, and Puma (Kim et al, 2006). Bcl-2 associated
death (Bad) promoter, Bcl-2 antagonist of cell death) is a
proapoptotic factor that promotes apoptosis via forming hetero-
dimers with prosurvival proteins Bcl-2 and Bcl-xL, preventing
them from binding with Bax (Yang et al, 1995). Phosphorylation of
Bad at Ser-112 and Ser-136 disrupts its association with Bcl-2 or
Bcl-xl, promoting cell survival (Datta et al, 2000; Hayakawa et al,
2000). Phosphorylation of Bad at ser-112 and ser-136 has
been proposed to be mediated by ERK/p90RSK1 and PI3K/AKT
pathways, respectively (Hayakawa et al, 2000). Thus, the
phosphorylation status of Bad at these critical serine residues
serves as a determinant of either cell death or survival (Downward,
1999). Data showing that a-TEA reduces phosphorylation of Bad at
both ser-112 and ser-136 sites suggest that the ability of a-TEA to
reduce AKT and ERK activities contributes to restoration of
Bad’s proapoptotic function. Furthermore, data showing that
inhibition of PI3K with wortmannin suppressed phosphory-
lation of Bad at both ser-112 and ser-136 supports a role for
PI3K in regulating both AKT and ERK/p90RSK1 in these
cells. Previous data from our lab showed that a-TEA induces
mitochondria-dependent apoptosis via activation of Bax, a critical
step in triggering mitochondria-dependent apoptosis (Yu et al,
2006; Jia et al, 2008b; Yu et al, 2010). Two other BH3-only
proapoptotic Bcl-2 members, caspase-8-mediated tBid (active
form of Bid) and p73-mediated Noxa, have been shown to be
upregulated by a-TEA (Yu et al, 2006; Jia et al, 2008b; Wang et al,
2008; Yu et al, 2010). In this study, for the first time,
we report that a-TEA induces Bad activation via inhibiting AKT
and ERK. These data demonstrate that a-TEA triggers mito-
chondria-dependent apoptosis via targeting different Bcl-2-
associated death promoters, namely, Bid, Noxa, and Bad, in
cancer cell types.
Caspase-9, a mitochondria-mediated initiation caspase, is
directly activated by Apaf-1 and cytochrome c and triggers
activation of execution caspases 3, 6, and 7, leading to DNA
fragmentation and cell death (Li et al, 1997). It has been reported
that caspase-9 activity is regulated by phosphorylation (Cardone
et al, 1998). AKT phosphorylates caspase-9 at Ser-196, leading
to inactivation of caspase-9 (Cardone et al, 1998). Therefore,
caspase-9 is another target for AKT to prevent cells from
undergoing apoptosis. Thus, a-TEA suppression of AKT phos-
phorylation of caspase-9 at ser-196 contributes to a-TEA-induced
mitochondria-dependent apoptosis.
Mammalian target of rapamycin is a downstream mediator of
PI3K/AKT signalling, regulating proliferation, survival, mobility,
and angiogenesis via targeting p70S6 kinase (p70S6K) and 4E-BP1
in breast cancers that exhibit constitutively activated PI3K/AKT
signalling (Bjornsti and Houghton, 2004). Accumulating evidence
suggests that PI3K/AKT/mTOR promote breast cancer cell survival
and resistance to chemotherapeutics such as trastuzumab
(a blocking antibody to Her-2) and tamoxifen (Hynes and Dey,
2009; Ghayad et al, 2010). The mTOR inhibitors rapamycin and
rapamycin analogues (CCI-779, RAD001, and AP23573) have
exhibited impressive growth inhibitory effects against a broad
range of human cancers, including breast cancer, in preclinical and
early clinical studies (Chan, 2004; Vignot et al, 2005). In this study,
we demonstrate that a-TEA functions as an mTOR inhibitor,
capable of suppressing mTOR by decreasing constitutively
activated mTOR (phosphorylated status of mTOR) and its
downstream mediators p70S6K and 4E-BP1. In addition, our data
show that a-TEA not only enhances rapamycin suppression of
mTOR and induction of apoptosis, but also suppresses rapamycin-
mediated feedback activation of AKT, providing a rationale for
developing a combination regimen of mTORþa-TEA for breast
cancer treatment.
Insulin receptor substrate-1 is an adaptor protein important for
the insulin receptor and IGF-1 receptor signal transduction to
downstream targets, including PI3K (Surmacz, 2000; Valentinis
and Baserga, 2001). It has important roles in maintaining
insulin sensitivity in adipocytes and cell growth in cancer cells
(Hartley and Cooper, 2002). Its activity is positively and negatively
regulated via its phosphorylation at different sites by not only
ligand-activated cell surface receptors but also by different
intracellular Ser/Thr protein kinases, including mTOR, ERK,
protein kinase C, and AMP-activated protein kinase, as well as
JNK (De Fea and Roth, 1997; Ozes et al, 2001; Rui et al, 2001;
Horike et al, 2003; Hiratani et al, 2005; Mingo-Sion et al, 2005).
Insulin receptor substrate-1 Ser-307 lies near the phospho-tyrosine
binding domain in IRS-1 and confers an inhibitory effect on both
insulin and IGF-1 signalling (Greene et al, 2003). Activation of JNK
has been established as a stress-mediated inducer of insulin
resistance in diabetic animal models via phosphorylation of IRS-1
at Ser-307, leading to inactivation of IRS-1 by interfering with the
interaction of the insulin receptor and IRS-1 and promoting IRS-1
degradation (Mamay et al, 2003). An inhibitory effect of JNK on
IRS-1 activity via phosphorylation at ser-307 in human breast
cancer cells has also been reported in Taxol treatments (Mamay
et al, 2003). In this study we report that a-TEA functions as an
IRS-1 suppressor in human breast cancer cells via JNK-dependent
phosphorylation of IRS-1 at ser-307. Thus, a-TEA-mediated
phosphorylation of IRS-1 at ser-307 is correlated with down-
regulation of total protein levels of IRS-1, and both a-TEA-
mediated phosphorylation of IRS-1 and downregulation of total
protein level of IRS-1 are JNK dependent, suggesting that a-TEA
downregulation of total protein level of IRS-1 may be subsequent
to phosphorylation of IRS-1 at ser-307, as phosphorylation of IRS-1
at ser-307 has been reported to decrease IRS-1 stability (Greene
et al, 2003). Mammalian target of rapamycin and ERK have been
reported to negatively regulate IRS-1 via their downstream
mediator p70S6K (Wan et al, 2007; Jiang et al, 2009), providing
a negative feedback mechanism for turning off activation of AKT
(Sun et al, 2005). Thus, inhibitors of MEK/ERK and mTOR
produce a counterproductive increase in pAKT via loss of the
negative feedback control of IRS-1 levels, which limits their clinic
applications. It is highly significant that a-TEA functions as an
inhibitor of not only ERK and mTOR, but also of AKT. It is also
highly significant that a-TEA in combination with ERK and mTOR
inhibitors blocks inhibitor-induced increases in pAKT. The potent
anticancer actions by a-TEA appear to be because of its ability to
inhibit IRS-1/PI3K via activation of JNK.
c-Jun N-terminal kinase, a proapoptotic mediator, has been
reported to be activated by a-TEA and involved in a-TEA-induced
Fas and Fas L protein expression in prostate cancer (Jia et al,
2008b), as well as p73/Noxa protein expression (Wang et al, 2008)
and CHOP/DR5 protein expression (Tiwary et al, 2010) in breast
cancer cells. In this study we report that JNK suppressed pro-
survival PI3K and its downstream mediators via targeting
IRS-1. These data demonstrate that JNK has a critical pleiotropic
role in a-TEA-induced apoptosis via both proapoptotic and
antisurvival mechanisms. Mechanisms involved in the initiation
of JNK activation in response to a-TEA are not fully under-
stood. However, our recent data show that JNK is at least
partially activated by endoplasmic reticulum (ER) stress in a-TEA-
induced apoptosis (Tiwary et al, 2010). Following ER stress, Ire1
is released from GRP78 in ER, leading to activation of ASK1
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svia TRAF2 (Xu et al, 2005). Apoptosis signal-regulating kinase 1
(ASK1) has been shown to be critical in ER stress-mediated
apoptosis and activation of JNK (Nishitoh et al, 2002). Thus,
ER stress-mediated ASK1 is a possible upstream mediator for
JNK activation.
In summary, the ability of a-TEA to target PI3K-mediated
prosurvival factors via JNK-mediated inhibition of IRS-1 not only
has a role in enhancing a-TEA-induced apoptosis by inhibition of
AKT, ERK, mTOR, and their downstream mediators, but also
suggests a novel means for preventing procancer impact of AKT
activation induced by ERK and mTOR inhibitors.
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